Quantcast

Aeterna Zentaris: Abstract on Diagnostic Use of Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130, to be Presented at Upcoming International Congress of Neuroendocrinology

July 8, 2010

QUEBEC CITY, July 8 /PRNewswire-FirstCall/ – Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ), (the “Company”) a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 7th International Congress of Neuroendocrinology, which will be held July 11 through 15, 2010, in Rouen, France. AEZS-130 (Solorel(TM)) is currently in a Phase 3 trial as a diagnostic test for growth hormone deficiency in adults.

    Poster Title:      "Use of the Orally Active Ghrelin Mimetic AEZS-130 as
                       a Simple Test for the Diagnosis of Growth Hormone (GH)
                       Deficiency (GHD) in adults (AGHD)", Merriam G.R., Yuen
                       K., Bonert V., Dobs A, Garcia J., Kipnes M., Molitch
                       M., Swerdloff R., Wang C., Cook d., Altemose I. and
                       Biller B.

    Presenter:         George R. Merriam, M.D., Professor of Medicine,
                       University of Washington
    Date and Time:     Wednesday, July 14, 2010, 3:30 pm -6 pm (local time)
    Poster Board #:    P2-98
    Location:          Law Faculty, Universite de Rouen

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.


Source: newswire



comments powered by Disqus